Wegovy Commercial Claims and What They Actually Mean for UK Patients

You saw an advert, here's why the UK picture looks different

Picture this: you're scrolling through a video platform late in the evening, and a slick Wegovy commercial appears. People are talking about energy, confidence, transformed routines. It's persuasive. And then you start wondering whether you can get the same thing in the UK, and for how much.

That curiosity is completely understandable. The frustrating part is that most of those commercials are made for a US audience, where direct-to-consumer pharmaceutical advertising is permitted. In the UK it is not. The Human Medicines Regulations 2012 prohibit the promotion of Prescription-Only Medicines to the public, and the MHRA is clear that GLP-1 medicines are not assessed or intended for quick or cosmetic weight loss. So the tone, the claims, and even the brand framing you see in a US commercial simply cannot be reproduced here, not legally, and not responsibly.

What that means practically: if you're looking for Wegovy in the UK, the route is through a clinical assessment with a registered prescriber, not through responding to an advertisement. The UK's licensed semaglutide treatment is the same medicine, but accessed through a process that puts clinical judgement first.

What the clinical evidence behind the commercial actually says

Strip away the production values of any pharmaceutical commercial and you're left with the underlying trial data. For Wegovy at the standard 2.4mg maintenance dose, the landmark STEP 1 study (68 weeks, adults with obesity or overweight and at least one weight-related condition) recorded an average body-weight reduction of around 15%. That's a meaningful figure, cited directly by the NHS medicines page for semaglutide.

Since then, semaglutide's evidence base has kept growing. The MHRA approved a 7.2mg maintenance dose in January 2026, with trials reporting an average weight reduction of approximately 20.7% over 72 weeks, approaching the results seen with tirzepatide. A dedicated single-dose 7.2mg pen was approved on 14 April 2026, designed with an auto-dosing mechanism and built-in covered needle. If you want to understand the formal NICE recommendation for semaglutide, the guidance and eligibility criteria are covered in detail here.

None of those figures are guaranteed for any individual. Trial results are averages from large populations; your own outcome depends on your starting point, your adherence, and the lifestyle changes you make alongside treatment. A prescriber who has reviewed your health history is better placed than any commercial to tell you what's realistic for you.

Cost, access, and what a legitimate UK service includes

Commercials rarely mention price transparently, and UK providers vary considerably. Private Wegovy costs in the UK depend on the dose and the provider; following Eli Lilly's September 2025 list-price adjustment for tirzepatide, the wider private GLP-1 market has seen prices shift, with typical private semaglutide costs ranging broadly by dose and supplier. Any legitimate price should include a prescription, clinical assessment, and some form of ongoing support, if a listing omits those, that's worth scrutinising.

There are no legitimate discount codes for prescription medicines from regulated UK pharmacies. If you've seen a Wegovy promotional offer that promises a code or a price that seems far below market rate, the MHRA has warned repeatedly about counterfeit and illegally sold weight-loss pens, fake pens have been found to contain insulin and other unlabelled substances. The only safe route is a pharmacy you can verify on the GPhC register.

At nume, the price covers the consultation, the prescription, the treatment, and free next-working-day tracked delivery. We don't run offers or promotions, partly because the law doesn't permit them for POMs, and partly because the value we offer isn't a discount, it's a service.

Deciding whether Wegovy is right for you

A commercial, by design, speaks to the broadest possible audience. It can't assess your medical history, check your current medications, or account for conditions that might affect suitability. A prescriber can. Wegovy is licensed for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. That's the starting point, not the full picture. The prescriber's role is to look at the whole person, not just a number.

If you're interested in how semaglutide compares with other options or want to understand the wider landscape of weight-loss treatments available in the UK, that context genuinely helps. And if you've already been on treatment elsewhere and want to transfer, a prescriber will want to see evidence of your current dose and recent clinical checks before continuing. The common questions about starting treatment cover a lot of the practical ground.

When you're ready to find out whether you're clinically suitable, our prescribers review every consultation the same day. Check your eligibility by starting a free consultation.